John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Avancées dans le traitement médical du cancer du pancréas Volume 26, numéro 8, Octobre 2019

  • [1] Neuzillet C., Tijeras-Raballand A., Bourget P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104.
  • [2] Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
  • [3] Neuzillet C, Gaujoux S, Williet N, et al. Pancreatic cancer : French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018 ; 50 : 1257-71.
  • [4] Rahib L., Smith B.D., Aizenberg R. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
  • [5] Cowppli-Bony A., Colonna M., Ligier K. Descriptive epidemiology of cancer in metropolitan France : Incidence, survival and prevalence. Bull Cancer. 2019;106:617-634.
  • [6] Bouvier A.M., Uhry Z., Jooste V. Focus on an unusual rise in pancreatic cancer incidence in France. Int J Epidemiol. 2017;46:1764-1772.
  • [7] Maisonneuve P., Lowenfels A.B. Risk factors for pancreatic cancer : a summary review of meta-analytical studies. Int J Epidemiol. 2015;44:186-198.
  • [8] Bosetti C., Rosato V., Li D. Diabetes, antidiabetic medications, and pancreatic cancer risk : an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol. 2014;25:2065-2072.
  • [9] Zohar L., Rottenberg Y., Twig G. Adolescent overweight and obesity and the risk for pancreatic cancer among men and women : a nationwide study of 1.79 million Israeli adolescents. Cancer. 2019;125:118-126.
  • [10] Canto M.I., Harinck F., Hruban R.H. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339-347.
  • [11] Yadav D., Lowenfels A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252-1261.
  • [12] Al-Hawary M.M., Francis I.R., Chari S.T. Pancreatic ductal adenocarcinoma radiology reporting template : consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146:291-304.e291.
  • [13] Marion-Audibert A.M., Vullierme M.P., Ronot M. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT : A Prospective Multicenter Study. AJR Am J Roentgenol. 2018;211:W217-W225.
  • [14] Petrelli F., Inno A., Barni S. Borderline resectable pancreatic cancer : More than an anatomical concept. Dig Liver Dis. 2017;49:223-226.
  • [15] Oettle H., Neuhaus P., Hochhaus A. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA. 2013;310:1473-1481.
  • [16] Neoptolemos J.P., Stocken D.D., Bassi C. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA. 2010;304:1073-1081.
  • [17] Neoptolemos J.P., Palmer D.H., Ghaneh P. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011-1024.
  • [18] Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018 ; 379 : 2395-406.
  • [19] Tempero MA, Reni M, Riess H, et al. APACT : phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol 2019 ;.(37 suppl. ; abstr #4000).
  • [20] Delpero J.R., Jeune F., Bachellier P. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma : Updates From a French Prospective Multicenter Study. Ann Surg. 2017;266:787-796.
  • [21] Versteijne E., Vogel J.A., Besselink M.G. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946-958.
  • [22] Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer : a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019 May 14. pii : djz073. doi : 10.1093/jnci/djz073.[Epub ahead of print].
  • [23] Van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1) : A randomized, controlled, multicenter phase III trial. J Clin Oncol 2019 ;.(36 suppl. ; abstr #LBA4002).
  • [24] Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib : The LAP07 Randomized Clinical Trial. JAMA 2016 ; 315 : 1844-53.
  • [25] Suker M., Beumer B.R., Sadot E. FOLFIRINOX for locally advanced pancreatic cancer : a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810.
  • [26] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-25.
  • [27] Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-703.
  • [28] Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet 2016 ; 387 : 545-57.
  • [29] Oettle H., Riess H., Stieler J.M. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423-2429.
  • [30] Gill S., Ko Y.J., Cripps C. PANCREOX : A Randomized Phase III Study of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol. 2016;34:3914-3920. 32
  • [31] Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer : A randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol 2018 ; (36 suppl. : abstr 4000).
  • [32] Neuzillet C., Bachet J.B. Aspects moléculaires du cancer du pancréas : évolutions et révolutions ? Hépato-Gastro & Oncologie Digestive. 2017;24:61-69.
  • [33] Singh R.R., Goldberg J., Varghese A.M. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization : A scoping review. Cancer Treat Rev. 2019;75:27-38.
  • [34] Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019 ; 381 : 317-27.
  • [35] Hilmi M., Bartholin L., Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma : Where are we now? World J Gastroenterol. 2018;24:2137-2151.
  • [36] O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma : A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Jul 18. doi : 10.1001/jamaoncol.2019.1588.[Epub ahead of print].
  • [37] Le D.T., Durham J.N., Smith K.N. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413.
  • [38] Vedie A.L., Neuzillet C. Pancreatic cancer : Best supportive care. Presse Med. 2019;48:e175-e185.
  • [39] Hilmi M., Jouinot A., Burns R. Body composition and sarcopenia : The next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135-159.